A cell-free SDKP-conjugated self-assembling peptide hydrogel sufficient for improvement of myocardial infarction by Firoozi, S. et al.
biomolecules
Article
A Cell-Free SDKP-Conjugated Self-Assembling
Peptide Hydrogel Sufficient for Improvement of
Myocardial Infarction
Saman Firoozi 1, Sara Pahlavan 2, Mohammad-Hossein Ghanian 3 , Shahram Rabbani 4,
Shima Tavakol 5, Maryam Barekat 6, Saeed Yakhkeshi 2, Elena Mahmoudi 7,
Mansoureh Soleymani 5,* and Hossein Baharvand 2,8,*
1 Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in
Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran; saman.nano1989@gmail.com
2 Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for
Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran; sarah.pahlevan2007@gmail.com (S.P.);
saeedyakhkeshi@gmail.com (S.Y.)
3 Department of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and
Technology, ACECR, Tehran 1665659911, Iran; biomaterialist@gmail.com
4 Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center,
Tehran University of Medical Sciences, Tehran 1416753955, Iran; sh-rabbani@tums.ac.ir
5 Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran;
shima.tavakol@yahoo.com
6 Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology
and Technology, ACECR, Tehran 1665659911, Iran; barekat1001@yahoo.com,
7 Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA;
elena.mahmoudi@gmail.com
8 Department of Developmental Biology, University of Science and Culture, ACECR, Tehran 1461968151, Iran
* Correspondence: mansourehsoleimani@gmail.com (M.S.); Baharvand@Royaninstitute.org (H.B.);
Tel.: +98-21-8670-4714 (M.S.); +98-21-22306485 (H.B.); Fax: +98-21-8862-2533 (M.S.); +98-21-23562507 (H.B.)
Received: 4 December 2019; Accepted: 25 January 2020; Published: 30 January 2020


Abstract: Biomaterials in conjunction with stem cell therapy have recently attracted attention as
a new therapeutic approach for myocardial infarction (MI), with the aim to solve the delivery
challenges that exist with transplanted cells. Self-assembling peptide (SAP) hydrogels comprise a
promising class of synthetic biomaterials with cardiac-compatible properties such as mild gelation,
injectability, rehealing ability, and potential for sequence modification. Herein, we developed an
SAP hydrogel composed of a self-assembling gel-forming core sequence (RADA) modified with
SDKP motif with pro-angiogenic and anti-fibrotic activity to be used as a cardioprotective scaffold.
The RADA-SDKP hydrogel was intramyocardially injected into the infarct border zone of a rat model
of MI induced by left anterior descending artery (LAD) ligation as a cell-free or a cell-delivering
scaffold for bone marrow mesenchymal stem cells (BM-MSCs). The left ventricular ejection fraction
(LVEF) was markedly improved after transplantation of either free hydrogel or cell-laden hydrogel.
This cardiac functional repair coincided very well with substantially lower fibrotic tissue formation,
expanded microvasculature, and lower inflammatory response in the infarct area. Interestingly,
BM-MSCs alone or in combination with hydrogel could not surpass the cardiac repair effects of the
SDKP-modified SAP hydrogel. Taken together, we suggest that the RADA-SDKP hydrogel can be
a promising cell-free construct that has the capability for functional restoration in the instances of
acute myocardial infarction (AMI) that might minimize the safety concerns of cardiac cell therapy
and facilitate clinical extrapolation.
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1. Introduction
Myocardial infarction (MI) is the most prevalent among cardiac disorders and has high morbidity
and mortality rates [1]. Blockage of the coronary artery results in MI that is characterized by local
ischemia and apoptosis of conforming cardiac cells that include cardiac progenitor cells (CPCs),
cardiomyocytes, smooth muscle cells, and endothelial cells [2]. Inflammatory cells migrate to the
infarcted area and produce large amounts of reactive oxygen species (ROS) [3]. Thus, the cardiac
environment converts to an inflamed area with low oxygen levels, high amounts of ROS, large numbers
of apoptotic cells, and disintegrated extracellular matrix (ECM). Once inflammation is reduced, cardiac
tissue is replaced by scar tissue, which is accompanied by dilation of the left ventricle (LV) [4,5].
Conventional therapeutic approaches for MI have been developed based on revascularization by
different means such as balloon angioplasty or coronary artery bypass grafting [6]. Although mostly
successful, these revascularization methods could not fully inhibit ventricular remodeling due to
hypoxia in the infarct area. One major challenge is restoration or replacement of damaged myocardium.
Injured myocardium leads to development of dilated ventricles and consequent heart failure [7].
Cardiac cell therapy is a promising approach for myocardial regeneration [8]. Various cell sources
have been transplanted into the infarcted area to restore cardiac function via direct myogenesis
such as CPCs [9] and mesenchymal stem cells (MSCs) [10] or their paracrine effects on resident
cells such as CPCs [9], MSCs [10], endothelial progenitor cells (EPCs) [11], and hematopoietic stem
cells (HSCs) [11]. In particular, several clinical trials have been designed or conducted based on the
promising results of MSC therapy for MI (clinicaltrials.gov identifier: NCT03798353, NCT02323477,
NCT01392105, NCT00114452, NCT01291329). However, cardiac cell therapy has shown partial success,
which is likely due to low engraftment of the transplanted cells [12,13]. Both viability and retention
of the transplanted cells could be hampered by insufficient nutrition caused by lack of vasculature,
inflammatory conditions, and remodeled ECM in the fibrotic area [14].
To circumvent the challenges of cell therapy, tissue engineering has emerged as an option to
induce cardiac repair using biomaterial scaffolds as cell delivery vehicles or cell-free therapeutic agents.
With scaffold-mediated cell delivery, a higher rate of cell retention and viability could be achieved due to
greater cell–ECM interactions at the transplantation site [15]. More importantly, the biomaterial scaffolds
could work alone as a cell-free approach to induce cardiac repair by providing mechanical support
for the dilated ventricle and/or release of bioactive agents to induce angiogenesis, cell recruitment,
and immunomodulatory effects [16]. Hydrogels are a subgroup of biomaterials that have a high
water content and tunable crosslink density, which allows for controlled delivery of cells and other
bioactive agents [16–18]. Hydrogel-based scaffolds can be injected into the infarcted site via minimally
invasive surgical methods. Thus, they are of special interest as a therapeutic approach to prevent
adverse LV remodeling [19]. A vast pool of materials have been assessed for this purpose, and range
from natural polymers such as myocardial ECM [20], hyaluronate [21], collagen [22], fibrin [23], and
alginate [24] to synthetic polymers such as ureido-pyrimidinone-modified poly(ethylene glycol) [25]
and poly(N-isopropylacrylamide) [26]. Despite a wide range of preclinical studies with promising
outcomes, their translation to the clinic has been limited to a very few hydrogels that have reached
final phases of clinical trials. These include myocardial ECM hydrogel (clinicaltrials.gov identifier
NCT02305602) and alginate hydrogel (NCT3082508 and NCT01311791). Reasons for this unsuccessful
translation include safety concerns and batch-to-batch variations of the natural polymers, whereas the
alternative synthetic polymers usually suffer from poor bioactivity [27]. Self-assembling peptides (SAPs)
are a class of synthetic polymers that can be tailored to form bioactive hydrogels through biocompatible
supramolecular interactions. SAPs are composed of a series of hydrophobic and hydrophilic amino acids
that can be induced for structural organization by the addition of multivalent ions [28]. SAP hydrogels
have been used to treat MI in preclinical studies with promising outcomes [29–31]. In one study, an SAP
hydrogel with heparin-binding peptide motif that was amenable to vascular endothelial growth factor
(VEGF) and bFGF binding was injected at the site of injury in an acute MI model. The results showed
improved hemodynamic functions [32]. Recently, an MSC-laden SAP hydrogel was used in the form
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of epicardial coating at the site of infarction and resulted in enhanced left ventricular ejection fraction
(LVEF%) after four weeks [15].
The moldable synthesis of SAPs could allow for incorporation of bioactive peptide motifs to the
main hydrogel-forming oligopeptide, which is the core motif [28]. Herein, we conjugated a bioactive
motif (SDKP) with angiogenic, anti-inflammatory, and anti-fibrotic functions [33–37] to a common
core motif composed of four RADA sequences whose final product was an injectable supramolecular
hydrogel ((RADA)4-SDKP) The angiogenic potential of the (RADA)4-SDKP hydrogel was shown by
in vitro and ex ovo experiments. We applied the (RADA)4-SDKP hydrogel in a rat model of MI to
alleviate the inflammatory conditions and provide a permissive environment for revascularization
of the damaged myocardium. These features were confirmed by the results of in vivo analysis.
Interestingly, the cell-free hydrogel was highly cardioprotective, improved functional parameters and
reduced scar formation at the infarct area, and was comparable with the MSC-laden hydrogel.
2. Materials and Methods
2.1. Preparation of the (RADA)4-SDKP Hydrogel
RADA16-I was selected as the core due to its well-known ability for mild gelation via self-assembly [15],
GG was employed as spacer, and this construct was decorated with SDKP motif due to its biological
functions. RADA16-I was selected based on the design of a commercial product named PuraMatrixTM
(PuraMatrixTM, BD, Erembodegem, Belgium) [38,39] that has also been used for cardiac repair [2].
(RADA)4-SDKP peptide (N-terminus→C-terminus: Ac-RADARADARADARADAGGSDKP-NH2) was
custom synthesized by DG Peptides Co., Ltd. (Hangzhou, China). The (RADA)4-SDKP powder was
dissolved in deionized water (DEPS) at a concentration of 0.5%. Then, it was sonicated for 30 min
before the experiments. To prepare the hydrogel, we mixed the (RADA)4-SDKP solution with an equal
volume of phosphate-buffered saline (PBS) to form the gel with a final concentration of 0.25% after 1 min.
The 0.25% concentration of SAP hydrogel has been used before [40] and proposed by in vivo protocols of
PuraMatrixTM, which is composed of (RADA)4 hydrogel.
2.2. Characterization of the (RADA)4-SDKP Hydrogel
The viscoelasticity of SAP hydrogel was analyzed using a stress-controlled rheometer (Paar
Physica, MCR300 SN599139, EU). We injected 500 µL of the hydrogel into the lower plate (10 mm
diameter and 1 mm thickness). The upper plate (20 mm diameter) was lowered until it contacted the
gel surface, and the examination was done by oscillatory frequency sweeps (0.1–600 s−1, 0.5% strain).
The microstructure of the SAP hydrogel was assessed by a field emission scanning electron microscope
(FESEM) (MIRA3\Tescan, Brno, Czech Republic). For this purpose, 500 µl of the hydrogel were frozen
at −20 ◦C and lyophilized for 48 h. The obtained sponge was sputter coated with gold and observed
using FESEM.
2.3. Cytocompatibility of the (RADA)4-SDKP Hydrogel
2.3.1. Isolation of Neonatal Mouse Cardiomyocytes (NMCMs)
NMCMs were isolated from one-day-old pups according to a protocol described previously [41].
All animal studies were performed in accordance with guidelines approved by the Ethics Committee
of Royan Institute (Tehran, Iran IR.ACECR.ROYAN.REC.1398.192). Briefly, the hearts were excised
and rapidly rinsed in cold Hank’s balanced salt solution (HBSS, Gibco USA). All non-cardiac tissues
and the atria were carefully dissociated from the ventricles. Then, the ventricles were further rinsed
in cold HBSS to remove any remaining blood and then they were minced into small pieces. Next,
the pieces were treated with HBSS/trypsin (0.5 mg/mL) overnight at 4 ◦C on an orbital shaker at
80 rpm. After the predigestion step, warm culture medium that consisted of 75% Dulbecco’s Modified
Eagle Medium (DMEM, Gibco), 25% Media 199 (M-199, Gibco), 1% penicillin/streptomycin (pen/strep,
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Gibco), 1% l-glutamine (Gibco), and 1% 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES,
Gibco) was added to the trypsinized heart tissues. After discarding the predigestion media, the heart
tissue was subjected to serial digestions with an HBSS/collagenase II (0.8 mg/mL) solution on an orbital
shaker at 37 ◦C. Following the digestion steps, we collected the supernatants, centrifuged them at
800 rpm for 5 min at room temperature, and resuspended the cell pellet in culture media composed
of DMEM, M-199, 1% pen/strep, 1% l-glutamine, 1% HEPES, 20% horse serum (Gibco), and 10%
fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA). The cell suspension was preplated on 0.1%
gelatin-coated T-75 flasks for 1 h at 37 ◦C and 5% CO2 to remove the isolated cardiac fibroblasts and
obtain a homogeneous population of cardiomyocytes. Finally, the preplate supernatant was collected
and centrifuged, and the pellet of NMCMs was resuspended in culture media.
2.3.2. MTS Assay
The impact of (RADA)4-SDKP hydrogel encapsulation on metabolic activity and proliferation
of NMCMs was evaluated by MTS assay. Briefly, 1 × 104 NMCMs were cultured alone (control) or
encapsulated in the (RADA)4-SDKP hydrogel at a final concentration of 0.25% v/w into each well of a
96-well plate that contained culture media for 24, 48, and 72 h at 37 ◦C and 5% CO2 (n = 4). After each
incubation period, the cell-seeded plates or cell-laden gels (n = 4) were incubated for 4 h with MTS
reagent (Promega, USA) and the supernatant was analyzed for absorbance at 490 nm.
2.4. Angiogenic Potential of (RADA)4-SDKP Hydrogel In Vitro and Ex Ovo
2.4.1. In Vitro Vascular Endothelial Growth Factor (VEGF) Secretion Assay
VEGF release by human umbilical vein endothelial cells (HUVECs) was evaluated in two forms
of the cultured cells alone or encapsulated within (RADA)4-SDKP. For this purpose, HUVECs were
isolated from aseptic human umbilical cords that were received from Arash Hospital (Tehran, Iran)
after obtaining written consent from volunteer couples, as previously described [42]. The HUVECs
were cultured in EGM-2 supplemented with 10% FBS (10,270, Gibco). All in vitro experiments were
performed using passages 3–6 HUVECs, and the cells were incubated at 5% CO2 and 37 ◦C and tested
regularly for mycoplasma contamination by our laboratory. Then, 1 × 104 HUVECs were cultured
alone (control) or encapsulated into the hydrogel at a final concentration of 0.25% v/w onto each well of
a 48-well plate that contained the aforementioned medium for 24 or 124 h (n = 3). Next, conditioned
media from the cultured cells were collected and assessed by enzyme-linked immunosorbent assay
(ELISA) using a Human VEGF DuoSet ELISA DY293B-05 kit (R&D Systems, Minneapolis, Minnesota,
USA) according to the manufacturer’s instructions.
2.4.2. Chicken Chorioallantoic Membrane (CAM) Assay
Fertilized eggs from Hy-line W-36 hens were obtained from a commercial farm. The eggs were
cracked under a sterile laminar flow hood and the contents were transferred to a Petri dish. Each
embryo with the yolk was transferred to a surrogate shell, which was 3–4 g heavier than the egg
shell, sealed with plastic wrap, and allowed to incubate in a forced-air incubator for 60 h at 37 ◦C and
60% humidity. The embryonic day (ED) when the eggs were placed in the incubator was considered
to be embryonic day 0 (ED0). On ED2.5, the yolk-embedded embryo was transferred to a second
surrogate shell, which was 35 to 40 g heavier than the egg shell, sealed with plastic wrap, and allowed
to incubate for another 5 days. Dead or infected embryos were removed daily to avoid further
contamination. The chorioallantoic membrane (CAM) angiogenesis assay was performed as previously
described [43]. Briefly, O-ring paper filters that contained PBS (vehicle) or (RADA)4-SDKP hydrogel
at a final concentration of 0.25% v/w (gel) were deposited on the intact CAMs at ED9, at a location
distal from the embryo and proximal to the major blood vessels. The embryos were maintained in the
incubator for 72 h. At ED12, the embryos were transferred to the stage of a SZX16 Wide Zoom Versatile
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Stereo Microscope (Olympus, Yokohama, Japan) and images were taken from inside the O-rings.
The numbers of branches were calculated for five random images in each treatment and averaged.
2.5. Cardiac Repair by (RADA)4-SDKP Hydrogel
2.5.1. Establishment of an Acute Myocardial Infarction (AMI) Rat Model
All animal experiments were approved by the Royan Institute Ethics Committee in accordance
with the NIH Guidelines for the Care and Use of Laboratory Animals (NIH Publication No. 85e23,
revised 2010). Adult male Sprague Dawley rats (280–350 g) were anesthetized with intraperitoneal
(IP) injections of 0.1 mg/kg medetomidine (Laboratorios Syva, AEM, Spain) and 75 mg/kg ketamine
(Alfasan, Woerden The Netherlands). To maintain a deep level of anesthesia, intubation and mechanical
ventilation (Harvard, state abbreviation, USA) with a mixture of room air, oxygen, and 1% isoflurane
was performed. The chest area was shaved and a left thoracotomy was performed to expose the LV.
The rat model of AMI was achieved by permanent ligation of the left anterior descending artery (LAD)
with 6-0 monofilament silk suture material (Keyhan Teb, TehranIran). Validity of the AMI model was
evaluated by color change to pale at the vicinity of the ligation and echocardiographic measurement
one day after induction. Rats with EF < 40% were selected as AMI models.
2.5.2. Treatment Procedure
Human bone marrow mesenchymal stem cells (BM-MSCs) at passages 3–5 were used as the cell
source. The BM-MSCs were obtained from the Cell Bank (RSCB0178) of Royan Institute for Stem Cell
Biology and Technology (Tehran, Iran) whose bone marrow was taken from a 34-year-old healthy male
after written consent. The cells were cultured in α-MEM with 20% inactivated FBS that contained
l-glutamine, penicillin, and streptomycin. The AMI rats were randomly divided into four experimental
groups: Vehicle, Cell, Gel, and Gel + Cell. The Vehicle group received an intramyocardial injection of
PBS (100 µL) at four sites of the infarct border zone. The Cell group received 2 × 106 human BM-MSCs
in PBS (100 µL). The Gel group received 0.25% SAP hydrogel (100 µL) and the Gel + Cell group
received 2 × 106 BM-MSCs encapsulated in 0.25% SAP hydrogel (100 µL). Number of injected cells at
Cell and Gel + Cell groups was chosen based upon previous reports [44]. After cell and/or hydrogel
transplantation, each animal received an IP injection of 1 mg/kg atipamezole (Laboratorios Syva) and
the animal was kept in an oxygen chamber on a heating stage until recovery. A prophylactic antibiotic
((Enrofloxacin, 15 mg/kg, Rooyan Darou, Tehran, Iran) and analgesic (tramadol, 20 mg/kg, Darou
Pakhsh, Tehran, Iran) were injected IP for three days to prevent infection and pain.
2.5.3. Echocardiography Measurements
Functional evaluations of the hearts were performed by echocardiography using an ultrasound
system (Mindray, city, state abbreviation, Hamburg, Germany) 1 day before the AMI induction (Pre),
at day 1 after the AMI (Post1), and 4 weeks after the AMI (Post2). Rats were anesthetized by IP injections
of 0.1 mg/kg medetomidine and 75 mg/kg ketamine, and their chests were shaved. A cardiologist,
blinded to the treated groups, evaluated the cardiac function by ultrasound. Two-dimensional images
were taken to illustrate functional echocardiography parameters. End-diastolic and systolic volumes
were obtained to assess the LVEF. The changes in ejection fraction from day 1 to day 28 (∆EF) were
calculated and plotted. Fractional shortening (FS), the changes of fractional shortening from day 1 to
day 28 (∆FS), left ventricular inner diameter at diastole (LVIDd), and left ventricular inner diameter at
systole (LVIDs) were extracted and depicted. The rats were euthanized at week 4 and their hearts were
harvested for histological evaluations.
2.5.4. Histological Studies
On day 28, the hearts were excised and inundated in formalin 10% for 2 days. Following fixation,
processing, and embedding in paraffin, the sections were cut into 5µm increments. After deparaffinization
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and hydration, Masson’s trichrome (MT) staining was carried out on the heart sections. Then, percentage
of fibrotic areas were determined by ImageJ software (version 1.47, acquired from http://imagej.nih.gov/ij/).
The averaged infarct area was calculated from 12 slides in each animal, plotted, and compared between
the experimental groups.
Sections from apex, middle, and base levels of each animal heart were chosen. Immunofluorescence
staining of the deparaffinized and dehydrated sections was performed by subjecting the slides to
antigen retrieval with Target Retrieval Solution (pH 9, Dako, S2368, Glostrup, Denmark) for 20 min.
The sections were then permeabilized with 0.5% Triton X-100 at RT for 30 min, blocked for 1 h at 37 ◦C,
and incubated overnight with primary antibodies α-SMA (Abcam: ab7817, Cambridge, Massachusetts,
USA), CD68 (Sigma: 048982, Darmstadt, Germany), and STEM 121 (Clontech, Y40410, USA) at 4 ◦C.
Secondary antibody (anti-mouse IgG, Sigma, F9006) was applied at 37 ◦C for 1 h, counterstained with
DAPI, and the sections were observed under a fluorescence microscope (Olympus; BX51). To quantify
vascular density, the number of α-SMA+ structures at whole infarct zone of each section was assessed
and the average number was plotted for each animal as number of α-SMA+ structures/field of infarct
area [45]. Similarly, the numbers of CD68+ cells were counted in sections from apex, middle, and base
to assess infiltration amount of macrophages at the site of infarction and expressed as number of CD68+
cells/field of infarct area [46]. In order to track the transplanted MSCs, immunostaining of STEM121 as
specific antibody against a cytoplasmic protein of human cells was performed.
2.6. Statistical Analysis
All data are presented as mean ± standard deviation (SD). Statistical analysis was performed
using GraphPad Prism 8.0.1 software (San Diego, CA, USA) by one-way analysis of variance (ANOVA)
followed by the Tukey post-hoc test for comparisons between three or four groups and the Student’s
t-test for comparison between two groups. The survival experience in groups was analyzed by log-rank
(Mantel–Cox) and Gehan–Breslow–Wilcoxon tests. p < 0.05 was considered statistically significant.
3. Results
3.1. Structure and Characterization of Self-Assembling Peptide (SAP) Hydrogel
RADA16-I, as the core of the self-assembly, was decorated with the biologically active motif
SDKP to create (RADA)4-SDKP as the precursor of a bioactive SAP hydrogel (Figure 1A). Regarding
the HPLC assay that has been performed by DG Peptide company, a sharp single peak indicative of
a highly pure product was observed (Figure 1B). The peptide solution was converted to hydrogel
upon mixing with divalent calcium ions for less than 1 min (Figure 1C). Scanning electron microscopy
confirmed the SAP hydrogel microstructure. The presence of a nanofiber-like pattern of the SAP could
have been the result of binding and alignment of the peptide sequences following treatment with the
positively charged ions (Figure 1D). We evaluated the rheological features of the hydrogel to investigate
the changes in storage modulus (G′) and loss modulus (G”) with shear frequency as the elastic and
viscous terms of gel viscoelasticity, respectively. The prominent elastic behavior indicated by a higher
G’ value versus G” and the plateau behavior of both G’ and G” confirmed the successful sol–gel
transition (Figure 1E). The G′ and G” measurements indicated that a highly soft hydrogel was achieved,
which guaranteed its injectability. To investigate the cell encapsulation potential of the SAP hydrogel,
NMCMs were mixed with the (RADA)4-SDKP solution followed by calcium ion addition to enable
the mixture to gel. The metabolic activity of the encapsulated NMCMs within the (RADA)4-SDKP
hydrogel was assessed by MTS assay. The results showed no substantial change in cellular activity of
the encapsulated cells compared to the cells cultured on tissue culture plate (TCP) as a control after
24 h, 48 h, and 72 h, which showed that the self-assembly process was safe for cell encapsulation and
that the (RADA)4-SDKP hydrogel (0.25% concentration) was biocompatible (Figure 1F).
Biomolecules 2020, 10, 205 7 of 17
Figure 1. Structure and characterization of the self-assembling peptide (SAP) hydrogel. (A) Linear,
chemical and three-dimensional structure of the (RADA)4-SDKP as a precursor of the SAP hydrogel.
(B) HPLC graph related to (RADA)4-SDKP. (C) Visual illustration of gel formation by addition of Ca2+ to
the 0.25% (RADA)4-SDKP solution. (D) Field emission scanning electron microscope (FESEM) images
of 0.25% (RADA)4-SDKP hydrogel. (E) Viscoelasticity analysis of the 0.25% (RADA)4-SDKP hydrogel
using shear rheometry. (F) MTS assay to test the cellular activity of neonatal mouse cardiomyocytes
(NMCMs) after 1, 2, and 3 days of encapsulation in the (RADA)4-SDKP. MTS assay was performed in 3
biological replicates, each replicate included 4 repeats. Data are shown as mean ± standard deviation.
3.2. Angiogenic Potency of (RADA)4-SDKP
The angiogenic potential of the (RADA)4-SDKP hydrogel was assessed by measurement of VEGF
release and CAM assay. While VEGF release did not substantially differ between HUVECs plated on
TCP (338 ± 6.9 pg/mL) and those encapsulated in hydrogel (444 ± 92.2 pg/mL) after 24 h (p > 0.05),
the five-day culture in (RADA)4-SDKP scaffold resulted in markedly increased VEGF release compared
to the amount released by HUVECs cultured on TCP (455 ± 79.9 vs. 150 ± 19.8 pg/mL, respectively,
p ≤ 0.05; Figure 2A).
CAM is a popular angiogenesis model that is a highly vascularized membrane located beneath an
egg shell. Its location provides easy access for the application of diverse substances and monitoring vessel
growth in response to these substances in real time. (RADA)4-SDKP treatment for 72 h substantially
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increased vascular density distal to the region of the application compared to the vehicle, which indicated
its angiogenic potency (9.33 ± 1.5% vs. 5.33 ± 0.5%, p ≤ 0.05; Figure 2B).
Figure 2. Angiogenic potential of (RADA)4-SDKP hydrogel. (A) Vascular endothelial growth factor
(VEGF) release by human umbilical vein endothelial cells (HUVECs) cultured on either tissue culture plate
as the control (Ctrl) or encapsulated in 0.25% (RADA)4-SDKP (Gel) after 1 and 5 days. (B) Representative
images of the 0.25% (RADA)4-SDKP hydrogel placed on the chorioallantoic membranes (CAMs) at 0
and 72 h of incubation (n = 5, p ≤ 0.05). Quantification of blood vessel area demonstrated that the 0.25%
(RADA)4-SDKP hydrogel resulted in a statistically significant increase in response. Data are shown as
mean ± standard deviation (n = 3). * p < 0.05, ** p < 0.01.
3.3. Cardiac Functional Restoration by (RADA)4-SDKP
In an attempt to investigate the potential of the (RADA)4-SDKP hydrogel for cell delivery
as treatment for MI, we transplanted BM-MSCs by an intramyocardial injection and using the
(RADA)4-SDKP hydrogel as the carrier. Cardiac performance was assessed by echocardiography for
all groups (Vehicle, Cell, Gel, and Gel + Cell) 24 h before MI (Baseline), 1 day after MI induction (Post
1) and 28 days after MI induction (Post 2) (Figure 3A). Animal survival did not significantly differ
between all groups (Kaplan–Meier; Figure 3B). Echocardiographic measurements at baseline showed
normal cardiac function in selected animals (EF >70%, p > 0.05). After LAD ligation, the color of the
cardiac muscle became white from the point of the suture down to the apex, which indicated perfusion
disturbances and hypoxia. The ventricular ejection fraction was drastically reduced one day after MI
induction in all groups (EF <40%, p > 0.05). Of note, animals with post 1 EF >40% were excluded from
the experiment.
Four weeks of treatment with the Gel and Gel+Cell restored the LVEF to a large extent, which
was superior to that of the Cell and Vehicle groups as seen by the ∆EF of 20.33 ± 2.94 (Gel), 15.5 ± 3.01
(Gel + Cell), 5.8 ± 2.16 (Cell), and −3.2 ± 2.86 (Vehicle) with a p-value of <0.001 (Figure 3C,D).
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Figure 3. (RADA)4-SDKP hydrogel improved cardiac function after myocardial infarction (MI).
(A) Schematic representation of the in vivo study design. The study animal groups included
phosphate-buffered saline (PBS) as the Vehicle group, 2 × 106 bone marrow-derived mesenchymal
stem cells (BM-MSCs) as the Cell group, 0.25% (RADA)4-SDKP (Gel), and 2 × 106 MSCs encapsulated
within 0.25% (RADA)4-SDKP (Gel + Cell). We injected 100 µL of the individual treatments into the
peri-infarct region of the rats’ hearts 15 min after induction of an acute myocardial infarction (MI).
Next, echocardiographs were taken at 1 day before MI, 1 day after MI and 28 days after MI followed
by histomorphometric evaluations of the rats’ hearts. (B) Kaplan–Meier plot demonstrated increased
survival in the Gel and Gel+Cell groups compared with the Cell and Vehicle groups. (C) Ejection fraction
(EF) in all groups at pre-operation, and days 1 and 28 after MI. At day 28, EF was increased in all of the
treated groups compared with the Vehicle group. (D) Variations in EF from day 1 to day 28 (∆EF) was
higher in the Gel and Gel + Cell groups. (E) Fractional shortening (FS) in all groups at pre-operation,
days 1 and 28 after myocardial infarction are illustrated. On day 28, FS was higher in all treated groups
compared with Vehicle. (F) Variation of fractional shortening from day 28 to day 1 (∆FS) was greater in
Gel and Gel + Cell group. (G) Slight improvement was discernable in the parameter of the left ventricular
inner diameter at systole (LVIDs) for the Gel and Gel + Cell groups compared with the Vehicle group. (H)
Left ventricular inner diameter at diastole (LVIDd) did not differ significantly between groups. All data
are presented as mean ± standard deviation, n ≥ 5, * p < 0.05; ** p < 0.01; *** p < 0.005.
Consistent with the EF findings, contractile function of the LV showed improvement in the Gel and
Gel + Cell treatment groups compared to the Vehicle group, as shown by the ∆FS of 10.33 ± 2.02 (Gel)
and 7.33 ± 1.86 (Gel + Cell), p < 0.001 (Figure 3E,F). However, MSC transplantation did not markedly
restore ventricular contractility (∆FS: 3.6 ± 1.1 (Cell) vs. −1 ± 1.34 (Vehicle); Figure 3E,F). The LVIDs and
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LVIDd, which provide valuable information on contractile function of the LV and are used as indexes of
ventricular wall dilation progression, were analyzed in the treatment groups. There were substantially
smaller LVIDs in the Gel and Gel + Cell groups compared to the Cell and Vehicle groups (p < 0.05,
Figure 3G). However, LVIDd did not differ among all treatment groups (p > 0.05, Figure 3H).
Quantification of the fibrotic area showed that functional improvement coincided with smaller
scar formation in the infarct area of the rat hearts in the Gel (17.83 ± 4.9%) and Gel + Cell (12.5 ±
7.59%) groups compared with the Cell (41.5 ± 2.88%) and Vehicle (51.5 ± 5.44%) groups (p < 0.001,
Figure 4A,B).
These data revealed substantial restoration of cardiac function when infarcted rat hearts were
subjected to the Gel and Gel + Cell treatments. However, there appeared to be no marked differences
between the Gel and Gel + Cell treatments with respect to their functional improvements, which
highlighted the efficacy of the designated SAP hydrogel for cell-free cardiac functional restoration.
Figure 4. (RADA)4-SDKP hydrogel diminished scar size. (A) Representative images of Masson’s trichrome
(MT) stained heart sections at the apex, middle, and base areas for all groups. (B) At day 28, the infarct
area (% of left ventricle (LV)) was decreased in the Gel and Gel + Cell groups in comparison with the Cell
and Vehicle groups. All data are presented as mean ± standard deviation (n ≥ 4).*** p < 0.001.
3.4. Cardioprotective Mechanisms of (RADA)4-SDKP in Infarcted Rat Hearts
(RADA)4-SDKP treatment could efficiently inhibit the failure in cardiac functional reserve after
an MI, which we further investigated with respect to angiogenesis and inflammatory response in
the infarcted heart. Presence of SAP hydrogel in echocardiography images of post1 was confirmed
(Figure S1 and Supplementary Movie 1). However, it was absent in echocardiography images of post2
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(Figure S1) and all histological sections. Thus, we concluded that the hydrogel degraded completely
and disappeared after four weeks. Immunostaining by α-SMA showed a substantially larger number
of vessels in the infarct area of the LV following treatment with both the Gel (19 ± 3) and Gel + Cell
(16 ± 1) groups compared to the Vehicle group (9 ± 1, p < 0.05, Figure 5A). Consistent with in vitro
and CAM assays, (RADA)4-SDKP hydrogel augmented vascularization, which might underlie cardiac
functional restoration following the MI in the rats. We assessed the inflammatory response at the
infarct area by CD68 immunostaining as a marker of macrophages. There were considerably fewer
CD68-stained cells in the infarct areas of the hearts that received (RADA)4-SDKP hydrogel (20 ± 4)
or Gel + Cell (23 ± 6) compared to the Cell (40 ± 9) or Vehicle (52 ± 5) groups (p < 0.05, Figure 5B).
This finding indicated the probability of controlling the inflammatory response by this modified SAP
hydrogel, which was comparable with the anti-macrophage recruitment of MSCs in our experimental
setting. In order to check for BM-MSC retention after transplantation, STEM121 immunostaining was
performed to specifically identify human cells at the injection site. The results showed the presence of
STEM121+ cells when BM-MSCs were delivered by the (RADA)4-SDKP hydrogel (Figure 6).
Figure 5. (RADA)4-SDKP hydrogel increased angiogenesis and reduced inflammation. (A) More vessels
(α-SMA+ cells) were detected in the Gel and Gel + Cell groups compared with the Vehicle group. (B) A
lower number of CD68+ macrophages were observed in the Gel and Gel + Cell groups compared with
the Cell and Vehicle groups. All data are presented as mean ± standard deviation (n ≥ 3). * p < 0.05;
** p < 0.01.
Biomolecules 2020, 10, 205 12 of 17
Figure 6. Cell retention after hydrogel-mediated delivery. At the fourth week, encapsulated mesenchymal
stem cells (MSCs) that were injected into the myocardium were detected by immunostaining of STEM121
at the injection site.
4. Discussion
Adverse LV remodeling after MI directs cardiac tissue to a failing muscle, develops heart failure,
and increases mortality [47,48]. Several strategies have been investigated for cardiac protection
following MI, with over 6400 articles published since 1975; however, there is no ideal treatment
available for this purpose [8].
Regenerative therapy for ischemic heart diseases, including cell-based therapy and cell-free
approaches such as biomaterial scaffolds and delivery of bioactive molecules, is an active field of
research that has launched several potential treatment strategies [49].
The current study examined a novel hypothesis that SDKP-conjugated SAP hydrogel would
decelerate LV remodeling after AMI induction in rat hearts. This hydrogel could restore cardiac function.
Furthermore, the (RADA)4-SDKP hydrogel had the capability to deliver and retain BM-MSCs at the site
of the infarct. Thus, we designed a bioactive hydrogel that, in addition to an inherent cardioprotective
effect, could efficiently deliver cells and improve their retention. However, the appropriate cell source
should be further determined.
The SAP hydrogel has shown tremendous promise as a therapeutic biomaterial and addressed
numerous indispensable requirements for myocardial therapy and regeneration [30]. RADA is a class
of SAPs that can form supramolecular hydrogels upon mixing with the positively charged multivalent
ions. The RADA-based hydrogels are biocompatible and biodegradable, mimic the nanofibrous
structure of ECM, induce cell recruitment, and allow for sequence modification to render other
bioactive functions [50,51]. These hydrogels have been used for the engineering of various tissues with
low immunogenicity [52–54]. After injection of RADA16-II into the infarcted myocardium, the empty
space of the hydrogel was cellularized by endothelial, smooth muscle, and cardiac cells within days,
which showed the cell recruitment potential of the RADA-based hydrogels for endogenous regeneration
of infarcted myocardium [30,55]. In order to improve cardiac function, cardioprotective and angiogenic
cues such as IGF1 [56], PDGF [54], VEGF [57], FGF [58], Notch1 [16], and QHREDGS [59] have been
integrated with the SAP hydrogels.
Angiogenesis is a vital mechanism that may alleviate heart dysfunction after MI. Hence, one
of the key points in the regeneration of infarcted myocardium, either by resident progenitor cells or
cell therapy, is sufficient angiogenesis in the target zone. Formation of new vessels and an adequate
blood supply to the affected area reduces cardiomyocyte apoptosis and the level of fibrosis [34,60,61].
Some studies support the idea of SAP hydrogels modified with angiogenic motifs that promote cardiac
repair. One proposed mechanism was an increase in vascular density and vessel diameter [57,61].
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N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a tetrapeptide that has been well studied for
improvement of the adverse effects of MI. Suggested mechanisms for cardiac healing of SDKP include
enhancement of angiogenesis and reduction of fibrosis and inflammation [33–37]. Upon addition
of calcium ions to the (RADA)4-SDKP solution, the amino acids reorganize in a nanofiber-like
structure to form a supramolecular hydrogel without any chemical reaction. The safe conditions
of the physical crosslinking could allow for encapsulation of the viable cells during gel formation.
Moreover, the nanofibrous morphology might provide an ECM-mimetic microenvironment to support
functionality of the cells [31].
From the various cell sources, MSCs appear to be promising for transplantation in MI [47,62].
Encapsulation of MSCs in SAP hydrogels has been proposed to overcome low engraftment of the
cells and appeared to be beneficial in preclinical studies [15,63]. Consistent with previous studies,
our SAP hydrogel was highly soft (G’~60 Pa), which might provide enough flexibility to not disrupt
under heart beating [16]. In addition, the low density of the physical crosslinks could allow for
easy injection of the gel due to its shear-thinning potential throughout the needle. In vitro and ex
ovo assessments have shown the capability of the (RADA)4-SDKP hydrogel to induce angiogenic
responses. Myocardial injection of the (RADA)4-SDKP hydrogel (Gel) at the infarcted area restored
cardiac function after four weeks of follow-up. The higher probability of infarct area reduction, blood
vessel density increment, and inflammatory response alleviation might be attributed to inherent
properties of the SDKP motif, which is distributed in the entire structure of the hydrogel. However,
this should be further investigated. Particularly, it is of great value to investigate the three phases of
post-infarction inflammatory response [64] to address the time-dependent activation of macrophages.
These results agreed with other studies that have used SAPs in a cell-free approach [16,61,65]. We also
examined the potential of using the SAP hydrogel as a cell delivery vehicle. To this end, BM-MSCs
were encapsulated within the (RADA)4-SDKP hydrogel during gel formation to make a cocktail with
potential cardioprotective effect (Gel + Cell group). Of note, free injection of BM-MSCs did not show
restoration of cardiac function compared with the vehicle group. These data were expected due to the
probability of cell washout from contracting myocardium and poor retention. Furthermore, no trace of
the gel was detectable in the histological sections of 28 days’ post-treatment. This observation was
in agreement with the echocardiography observations where the injected gel was clearly detectable
on day 1, whereas it disappeared on day 28, suggesting complete degradation of the gel during the
four-week experiment. Nevertheless, the transplanted BM-MSCs were detectable after 28 days in the
infarct region when delivered by the SAP hydrogel as was confirmed by STEM121 expression, as a
human cell marker.
We observed similar results on the evaluated cardiac parameters after both Gel and Gel + Cell
treatments. Ichihara et al. combined SAPs and MSCs to improve engraftment via epicardial coating,
which led to enhanced echocardiographic metrics of the infarcted hearts [15]. Thus, besides its inherent
cardiac anti-remodeling effect following MI, (RADA)4-SDKP can be combined with an appropriate
cell source to enhance the efficiency of cell therapy. In general, cell-free systems such as this modified
self-assembling peptide could provide highly competitive approaches for regenerative therapy of MI.
5. Conclusions
Delivery of a 0.25% (RADA)4-SDKP hydrogel to the infarcted rat heart as a cell-free SAP-based
scaffold resulted in improved cardiac function coupled with increased vessel formation and reduced
fibrosis and inflammation. Intramyocardial injection of (RADA)4-SDKP hydrogel could be an effective
acellular therapy for myocardial repair with the possibility for clinical translation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/2/205/s1,
Figure S1: Presence assessment of SAP hydrogel at Post1 and Post2, Movie S1: Presence assessment of SAP
hydrogel at Post1.
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